Full access to Entrepreneur for $5
Subscribe

Humana (HUM), Curant Health Team Up to Aid Chronic Patients

Humana (HUM) inks a deal with Curant Health to offer its members with chronic diseases enriched healthcare facilities.

By
This story originally appeared on Zacks

Humana Inc. HUM formed an alliance with Curant Health for enhancing the health experiences of Humana members who are suffering Chronic Heart Failure and Chronic Obstructive Pulmonary Disease.

- Zacks

This new pilot program intends to increase medication adherence to enable patients to lead better lives as well as decrease medical expenses.



Humana members with complicated health conditions will now leverage comprehensive support from this unique tie-up. Curant Health is a Medication Care Management organization with expertise in high-touch clinical aid for patients with chronic conditions.



This deal focuses on curbing adverse drug reactions, thereby lowering the need for hospital admissions. Both companies are committed to offer a better member experience.



This only helps the company utilize Curant Health’s innovative approach to customize patient care and data-driven insights that eventually facilitates the intake of prescription medicines.



This is not the first time that the health insurer took steps to ensure patient safety.



In July, Humana entered into a multi-year tie-up with Montefiore, one of New York’s premier academic health systems, to provide its Medicare Advantage members with access to the health system’s in-network medical care. The leading health insurer forged this partnership to widen the availability of the top-notch healthcare facilities among its current and future members.



In a year's time, the stock has gained 5.8%, underperforming its industry's growth of 33.2%. However, its series of acquisitions and dispositions, efficient capital deployment and a strong Medicare business position it for long-term gains. The company’s Medicaid business has also been contributing to its top line for years now on the back of contract wins.

Zacks Investment Research

Image Source: Zacks Investment Research

The company presently holds a Zacks Rank #4 (Sell).



You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.



Other companies in the same space, such as The Joint Corp.  JYNT, Molina Healthcare, Inc. MOH and UnitedHealth Group Incorporated UNH have also surged 473.3%, 52.9% and 38.4% in the same time frame.

 



Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>



Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report

 

Humana Inc. (HUM): Free Stock Analysis Report

 

Molina Healthcare, Inc (MOH): Free Stock Analysis Report

 

The Joint Corp. (JYNT): Free Stock Analysis Report

 

To read this article on Zacks.com click here.

 

Zacks Investment Research